Kornimate/medical-research-clean huggingface dataset:
therasphere for the treatment of liver metastases

Conditions: Colorectal Cancer; Carcinoma, Neuroendocrine; Neoplasm Metastasis

Summary: this study will evaluate liver progression free survival (pfs) and safety of therasphere treatment at doses of 120 gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of metastatic disease to the liver that is refractory to, or inappropriate for, other systemic or liver-directed therapies * unresectable liver metastases * target tumors measurable using standard imaging techniques * tumor replacement \< or = 50% of total liver volume (visual estimation by investigator) * hypervascular tumors (visual estimation by investigator) * eastern cooperative oncology group (ecog) performance status 0 - 2 * minimum one month since most recent prior cancer therapy with the exception of patients receiving sandostatin for neuroendocrine cancer * patient informed consent exclusion criteria: * at risk of hepatic or renal failure within 21 days of treatment (serum creatinine \> 2.0 mg/dl unless on dialysis; serum bilirubin ≥ 2.0 mg/dl; albumin \< 2.0 mg/dl or any history of hepatic encephalopathy) * contraindications to angiography and selective visceral catheterization including any non-correctable bleeding diathesis or coagulopathy, severe peripheral vascular disease or history of non-management allergy or intolerance to contrast, narcotics, sedatives or atropine * severe liver dysfunction or presentation of pulmonary insufficiency or clinically evident history of chronic obstructive pulmonary disease * cirrhosis or portal hypertension * prior external beam radiation treatment to the liver * prior therasphere treatment to the liver * any intervention for, or compromise of the ampulla of vater * clinically evident ascites (trace ascites on imaging is acceptable) * any continuing complications of prior cancer therapy that have not improved or resolved prior to 21 days before first therasphere treatment * significant life-threatening extrahepatic disease in judgment of physician * concurrent enrollment in another study * alternative available therapies in judgement of physician * evidence on technetium-99m macroaggregated albumin scan that shows lung shunting \> 30 gy cumulative limit * evidence on technetium-99m macroaggregated albumin scan showing potential for deposition of microspheres to the gastrointestinal tract that cannot be eliminated by catheter placement or corrective action using standard angiographic techniques * positive serum pregnancy test in women of childbearing potential * co-morbid disease or condition that puts the patient at undue risk or precludes use of therasphere in judgment of physician

Keywords: therasphere radioactive microspheres yttrium-90 yttrium glass microspheres
a phase ii trial of cyberknife stereotactic radiosurgery to prostate tumors

Conditions: Prostate Cancer; Cancer of the Prostate; Prostate Neoplasm

Summary: the purpose of this study is to determine the effects of cyberknife radiosurgery in patients with early stage prostate cancer. the investigators hypothesize that hypofractionated stereotactic radiotherapy via the cyberknife® can deliver tumor ablating doses of radiation to prostate tumors safely and effectively while sparing the adjacent tissues (rectum, bladder, ureters, urethra, penile bulb, and bowel) from receiving damaging doses of radiation.

the cyberknife system is a type of radiation machine that uses a special system to precisely focus large doses of x-rays (radiation) on the tumor. the device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal.

Eligibility criteria:
inclusion criteria: * male age ≥ 21 * histologically proven prostate adenocarcinoma * clinical stage t1b-t2b, n0-nx, m0-mx (ajcc 6th edition) * psa ≤ 20 ng/ml * prostate volume ≤ 100 cc patients belonging in one of the following risk groups: * low: * cs t1b-t2a and gleason 2-6 and psa ≤ 10 * intermediate: * cs t2b and gleason 2-6 and psa ≤ 10, or * cs t1b-t2b, and gleason 2-6 and psa ≤ 20 ng/ml or gleason 7 and psa ≤ 10 ng/ml exclusion criteria: * any histology other than adenocarcinoma * age \< 21 * kps \<= 40 \<70 * ecog performance status ≥ 2 * patient weight \>350 lbs. (table limitation) * prior xrt to prostate or lower pelvis * prior surgery or cryotherapy to prostate * implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion * chemotherapy for a malignancy in the last 5 years * history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years * hormone ablation for 2 months prior to enrollment, or during treatment

Keywords: prostate cancer cyberknife stereotactic radiation
long-term beta-blocker therapy after acute myocardial infarction

Conditions: Myocardial Infarction

Summary: the aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (hf) or left ventricular systolic dysfunction after acute myocardial infarction (ami). prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without hf or left ventricular systolic dysfunction after ami.

β-blockers have anti-ischemic, anti-arrhythmic, and anti-adrenergic properties. in order to reduce cardiovascular mortality and morbidity, current major guidelines recommend that oral treatment of β-blockers should be continued during and after hospitalization in patients with acute myocardial infarction (ami) and without contraindications to β-blocker use. a clinically important but difficult decision on β-blocker therapy after ami is to determine the duration of β-blocker therapy after discharge in patients without heart failure (hf) or left ventricular systolic dysfunction. previous studies for long-term β-blocker therapy after ami were inadequate to derive definite conclusion because of small sample size and potential selection bias. therefore, the smart-decision trial will investigate whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without hf or left ventricular systolic dysfunction after ami.

Eligibility criteria:
inclusion criteria: * subject must be at least 19 years of age. * subject who have been continuing β-blocker therapy for at least 1 year after acute myocardial infarction regardless of the time of diagnosis * subject is able to verbally confirm understandings of risks and benefits of this trial, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. exclusion criteria: * subject whose left ventricle ejection fraction was less than 40% from echocardiography performed after acute myocardial infarction or who have never received echocardiography. * treatment history of heart failure * contraindication to β-blocker therapy (history of symptomatic bronchial asthma or chronic obstructive pulmonary disease, 2nd or 3rd degree av block, cardiac pacemaker implantation, or other cases where β-blocker cannot be used under the judgment of the clinician) * non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment). * history of atrial fibrillation * pregnancy or breast feeding
evaluation of the root resorption and dehiscence formation between two methods of leveling and alignment of lower teeth

Conditions: Crowding of Anterior Mandibular Teeth

Summary: the duration of orthodontic treatment is one of the exacerbation causes of orthodontic pain. several methods have been suggested to reduce the duration of orthodontic treatment classified to surgical and non-surgical methods. researchers used minimally invasive surgical methods like corticision, piezocision, micro-osteoperforation, and piezopuncture indicated that most of these methods can accelerate dental movement by 20 - 40%. the effect of corticision as a minimally invasive procedure on root resorption and dehiscence formation during orthodontic tooth movement has not been studied yet. applying corticision on the lower anterior teeth using a surgical blade and a hammer may accelerate tooth alignment during orthodontic treatment. this study consists of two groups, patients will be randomly assigned to one of these two groups.

orthodontically induced external root resorption accompanying orthodontic treatment is defined as a microscopic loss of root tissue as a result of the inflammatory reaction that occurs in the area of application of orthodontic force. it can be diagnosed and measured using conventional radiography or cone-beam computed tomography (cbct). dehiscence is a loss of alveolar bone on the facial (rarely lingual) aspect of a tooth that leaves a characteristic v-shaped, root-exposed defect from the cementoenamel junction apically. bone dehiscence cannot be detected through conventional radiography or clinical examination. actually, cbct can be considered the best accessible technique providing 3d data. corticision is one of the minimally invasive surgical procedures that is not associated with flap lifting. it was used to accelerate tooth movement in animals and case report studies. its application on humans may aggravate their fear and anxiety towards the pain that may accompany this technique. no randomized controlled trial (rct) has compared flapless corticision in the non-extraction-based orthodontic decrowding of lower anterior teeth (lat) with the conventional treatment in terms of external apical root resorption (earr) and dehiscence formation (df).

Eligibility criteria:
inclusion criteria: 1. age range between 18 and 24 years 2. completion permanent dentition (except third molars) 3. mild to moderate crowding (2-6 mm according to little's index) 4. absence of medications intake that interferes with pain perception for at least one week before the beginning of the treatment exclusion criteria: 1. medical conditions that would affect tooth movement. 2. cases which contraindication to oral surgery. 3. previous orthodontic treatments.
analysis of relevant influencing factors of glycemic control in patients with diabetes

Conditions: Glycemic Control

Summary: this study aims at the analysis of relevant influencing factors of glycemic control in patients with diabetes.


Eligibility criteria:
inclusion criteria: patients aged 18-90 years with diabetes and the diagnostic criteria of diabetes is according to the world health organization in 1999. exclusion criteria: patients with stress hyperglycaemia. patients with severe systemic disease. patients treated with systemic glucocorticoids within the last three months. patients without any records about hba1c, cgm and smbg.
conventional home exercise programs versus electronic home exercise versus artificial intelligence "virtual therapy" for anterior knee pain

Conditions: Patellofemoral Pain Syndrome

Summary: this is a clinical research trial to evaluate the efficacy of delivering exercise therapy for knee pain via the internet utilizing an algorithm designed to adjust a home exercise program based on user input. the investigators hypothesize that exercise therapy can be delivered safely and effectively with increased participant satisfaction compared to the current standard.


Eligibility criteria:
inclusion criteria: * age 18-64 with anterior knee pain * have computer access * cleared for exercise by a medical professional, if not possible or a medical professional on the study team over the phone and the par-q (physical activity readiness questionnaire) * have consented to participate in the trial exclusion criteria: * age \ 64 * screened as unsafe for exercise by a medical professional or the, study team and/ or screened out by the par-q * does not consent to the trial

Keywords: knee pain anterior knee pain patellofemoral patellofemoral syndrome runners knee
the effect of theoretical knowledge on resident's practical performance in musculoskeletal ultrasound

Conditions: Musculoskeletal Diseases

Summary: musculoskeletal ultrasound( msus) is highly operator-dependent and proper training is needed to ensure appropriate use and minimize risk of incorrect image interpretation.to acquire skills in msus, it is mandatory to assure training in both the cognitive ability to recognize normal and pathological findings within the images and the psychomotor component of the examination. this study will examine the effect of a novel developed e-learning platform "the ultrasound learning platform (ulna)", on pre- and post-course musculoskeletal ultrasound performance of rheumatology residents. moreover, to examine the resident's satisfaction with the e-learning platform ulna.


Eligibility criteria:
inclusion criteria: residents working in denmark. participants are required to have a medical license and provide informed consent before inclusion exclusion criteria: 1. no informed consent 2. existing the danish society for rheumatology (drs) level 1 or higher. 3. participation in prior studies involving musculoskeletal ultrasound training

Keywords: training ultrasound e-learning
healthy sport project; preventing eating disorders in sport

Conditions: Eating Disorders; Body Dissatisfaction; Disordered Eating; Adolescent - Emotional Problem; Athletic Injuries

Summary: the "healthy sport project" is an adapted program from the body project by prof eric stice, aiming to reduce body dissatisfaction and symptoms of disordered eating and eating disorders in adolescent elite athletes. this trial aim to evaluate the effect of the program using a one-arm pilot study design in 14 years age old athletes at a norwegian elite sport junior high school.

eating disorders (eds) are serious illnesses with highest incidence in adolescents. moreover, athletes have a higher frequency of symptoms of disordered eating (de) and eds than non-athletes. there are many reasons to this health issue, but body appearance pressure, competing in body mass sensitive sports, and comments on body appearance are important explanations. few programs have proved effective in preventing de and eds in the general population, or in athletes specifically, and none is permanent operative in sports in norway. body project by prof eric stice have proved effective in preventing body dissatisfaction, figure idealization and new onset of eds in female adolescents above 15 years of age, and with body dissatisfaction, from the general population. a few attempts to adapt this program to female athletes, argue for a comparative positive effect. three important elements to further address, are: 1) programs need also to be tested in males; 2) programs need to be tested in adolescents of younger age before the typical onset of an ed; and 3) programs need to be possible to administer by non-professionals. in this study the research group aim to adapt and test the effect of the body project, by the pilot study the "healthy sport project", in elite junior athletes attending specialized junior sport high schools (age 14). the final goal for this project group is to create an effective preventive program for body dissatisfaction and de/eds in young athletes of both sexes and in mixed sports, and which may be administered by the schoolteachers.

Eligibility criteria:
inclusion criteria: * pupil at the recruited sport jr high school exclusion criteria: * no informed consent from parents * not willing to participate * a diagnosis of an eating disorder and being under (or waiting for) treatment

Keywords: eating disorders disordered eating body dissatisfaction figure idealisation mental health prevention athlete sport adolescent elite sport
value of analysing under-utilised leftover tissue (vault)

Conditions: Oncology

Summary: intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. it also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. by blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.

in order to establish the feasibility of homogenization as a potential companion diagnostic tool, our study aims to 1) evaluate how many surgical cases have left over tissue amenable to homogenization and 2) pilot homogenization across multiple tumour types. the molecular profile of the homogenate will be compared to that obtained from the diagnostic specimen using next generation sequencing techniques.

Eligibility criteria:
inclusion criteria: 1. leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery. 2. tissues for research consent has been provided. 3. patient age \>18yo. 4. minimum of 1 gram of residual tumour remaining in leftover surgical tissue 5. minimum of 1 gram of normal tissue present. exclusion criteria: 1. advanced practitioner in histological dissection deems tumour sample to be inadequate. 2. leftover surgical tumour tissue greater than 20kg.
clinical assessment of barley and oat phytochemicals

Conditions: Healthy

Summary: the goal of this placebo-controlled, 3-way crossover study is to determine the acute (24-h) bioavailability and pharmacokinetics of the major phytochemicals found whole barley and oats, as well as their effects on selected measures of antioxidation, inflammation, insulin sensitivity/glucose regulation, and vascular remodeling following challenge by an oral glucose tolerance test (ogtt).


Eligibility criteria:
inclusion criteria: * men and postmenopausal women * bmi 27-35.9 kg/m2 exclusion criteria: * cigarette smoking and/or nicotine replacement use * individuals taking estrogen * use of cholesterol-lowering medications * use of blood pressure-lowering medications * regular use of any stomach acid-lowering medications or laxatives (including fiber supplements) * cardiovascular (heart) disease * gastrointestinal disease * kidney disease * endocrine disease: including diabetes, untreated thyroid disease * rheumatoid arthritis * active treatment for any type of cancer, except basal cell carcinoma, within 1 year prior to study admission * systolic blood pressure \> 150 mmhg and/or diastolic blood pressure \> 95 mmhg * regular use of oral steroids * regular daily intake of ≥ 2 alcoholic drinks * infrequent or excessive number of regular bowel movements * illicit drug use * vegetarians * no fish oil supplements (including cod liver oil) for one month prior to study admission * no dietary supplements, including those containing any vitamins, minerals, herbs, plant concentrates (including garlic, gingko, st. john's wort) or homeopathic remedies, for one month prior to study admission

Keywords: oat barley whole grain bioavailability phytochemical
abdominal compartment syndrome and ruptured aortic aneurysm : validation of a predictive test

Conditions: Abdominal Compartment Syndrome

Summary: it is an observational study on ruptured abdominal aortic aneurysm and abdominal compartment syndrome. the aim of this study is to assess the qualities of a predictive score on the occurence of this syndrome after surgery of ruptured aortic aneurysm

despite improved management techniques of ruptured abdominal aortic aneurysm, especially in vascular surgery, the mortality rate has not decreased these last years. the abdominal compartment syndrome (acs) has been clearly identified as one of the main etiologies of mortality after ruptured aortic aneurysm. the mortality grow up with acs in this population. so, the investigators want to screen abdominal compartment syndrome in the operative room. it is an observational study on ruptured abdominal aortic aneurysm and abdominal compartment syndrome. the aim of this study is to assess the qualities of a predictive score on the occurence of this syndrome after surgery of ruptured aortic aneurysm later the aim of a future study will be to screen acs and manage patient as soon as possible to avoid it.

Eligibility criteria:
inclusion criteria: * over 18 * to be hospitalized in participating hospitals * ruptured aneurysm confirmed and operated exclusion criteria: * pregnancy * patients with bladder tumor or bladder surgery or trauma bladder can distort bladder pressure measurement * cystectomy * patients died before arrival in the operating room * patients died during surgery or within one hour of the initial surgical procedure * patient whose abdominal closure at the end of the procedure is impossible

Keywords: abdominal compartment syndrome abdominal aortic aneurysm ruptured aneurysm
an observational study of xeloda (capecitabine) in patients with metastatic colorectal cancer (axiom)

Conditions: Colorectal Cancer

Summary: this prospective observational study will evaluate the safety and efficacy of xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. patients will be followed until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * metastatic colorectal cancer * receiving xeloda according to registered indication exclusion criteria: * patients who are not eligible for xeloda treatment according to the summary of product characteristics
longterm-evaluation of vitelene® against standard

Conditions: Osteoarthritis, Hip; Arthritis

Summary: the purpose of this randomised prospective multicenter longterm study is to evaluate the survival rate of the implant, wear and periprosthetic osteolysis of highly cross-linked polyethylene with and without addition of vitamin e (uhmwpe-xe vs. uhmwpe-x) in total hip arthroplasty.


Eligibility criteria:
inclusion: * minimum age: 18 years * maximum age: 75 years * indication of cementless tha * approval of study participation and treatment according to study protocol * physical and mental willingness of adhering to clinical and radiological follow up exclusion: * patient is not able to join follow up * increased risk of anaesthesia according to the "american society of anesthesiology": asa iv * tumor disease * alcohol and drug dependency * permanent cortisone therapy * clinical relevant infections * pregnancy and planned pregnancy * previous interventions like adjustment-osteotomy, treatment of fractures or tha on affected side * acute fractures of the affected hip joint * patients with bone quality, which doesn´t allow a cementless treatment * requirements of clinical relevant deformities (condition after preoperation or bone fracture, leg length discrepancy \> 30 mm, offset-reduction about \> 30 mm) * small acetabular treatments with 28 mm heads * treatments without using ceramic heads * treatments which require neck prolonging components